Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

Vaccination in Multiple Sclerosis: Friend or Foe?

Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl UK.

Front Immunol. 2019 Aug 7;10:1883. doi: 10.3389/fimmu.2019.01883. eCollection 2019. Review.

PMID:
31440255
2.

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis.

Frahm N, Hecker M, Zettl UK.

Biol Sex Differ. 2019 May 27;10(1):27. doi: 10.1186/s13293-019-0243-9.

3.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27.

4.

A smart peek: Processing of rapid visual displays is disturbed in newly diagnosed, cognitively intact MS patients and refers to cognitive performance and disease progression in late stages.

Fischer M, Köhler W, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Zettl UK, Bublak P; HIPPOCOMS Study Group.

J Neurol Sci. 2019 Jun 15;401:118-124. doi: 10.1016/j.jns.2019.04.031. Epub 2019 Apr 23.

PMID:
31075683
5.

Aberrant expression of alternative splicing variants in multiple sclerosis - A systematic review.

Hecker M, Rüge A, Putscher E, Boxberger N, Rommer PS, Fitzner B, Zettl UK.

Autoimmun Rev. 2019 Jul;18(7):721-732. doi: 10.1016/j.autrev.2019.05.010. Epub 2019 May 4. Review.

PMID:
31059848
6.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
7.

The Cerebrospinal Fluid in Multiple Sclerosis.

Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK.

Front Immunol. 2019 Apr 12;10:726. doi: 10.3389/fimmu.2019.00726. eCollection 2019. Review.

8.

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Abdelhak A, Hottenrott T, Morenas-Rodríguez E, Suárez-Calvet M, Zettl UK, Haass C, Meuth SG, Rauer S, Otto M, Tumani H, Huss A.

Front Neurol. 2019 Mar 26;10:280. doi: 10.3389/fneur.2019.00280. eCollection 2019.

9.

Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases.

Boxberger N, Hecker M, Zettl UK.

J Immunol. 2019 Apr 15;202(8):2177-2187. doi: 10.4049/jimmunol.1801416. Review.

PMID:
30962309
10.

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.

Frahm N, Hecker M, Zettl UK.

Sci Rep. 2019 Mar 6;9(1):3743. doi: 10.1038/s41598-019-40283-5.

11.

A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene.

Hecker M, Boxberger N, Illner N, Fitzner B, Schröder I, Winkelmann A, Dudesek A, Meister S, Koczan D, Lorenz P, Thiesen HJ, Zettl UK.

PLoS Genet. 2019 Feb 7;15(2):e1007961. doi: 10.1371/journal.pgen.1007961. eCollection 2019 Feb.

12.

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study.

Frahm N, Hecker M, Zettl UK.

PLoS One. 2019 Jan 24;14(1):e0211120. doi: 10.1371/journal.pone.0211120. eCollection 2019.

13.

TPP2 mutation associated with sterile brain inflammation mimicking MS.

Reinthaler EM, Graf E, Zrzavy T, Wieland T, Hotzy C, Kopecky C, Pferschy S, Schmied C, Leutmezer F, Keilani M, Lill CM, Hoffjan S, Epplen JT, Zettl UK, Hecker M, Deutschländer A, Meuth SG, Ahram M, Mustafa B, El-Khateeb M, Vilariño-Güell C, Sadovnick AD, Zimprich F, Tomkinson B, Strom T, Kristoferitsch W, Lassmann H, Zimprich A.

Neurol Genet. 2018 Nov 13;4(6):e285. doi: 10.1212/NXG.0000000000000285. eCollection 2018 Dec.

14.

Headache in the course of multiple sclerosis: a prospective study.

Gebhardt M, Kropp P, Hoffmann F, Zettl UK.

J Neural Transm (Vienna). 2019 Feb;126(2):131-139. doi: 10.1007/s00702-018-1959-0. Epub 2018 Nov 30.

PMID:
30506270
15.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

16.

Headache at the Time of First Symptom Manifestation of Multiple Sclerosis: A Prospective, Longitudinal Study.

Gebhardt M, Kropp P, Hoffmann F, Zettl UK.

Eur Neurol. 2018;80(3-4):115-120. doi: 10.1159/000494092. Epub 2018 Oct 26.

PMID:
30368493
17.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

18.

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.

Rommer PS, Eichstädt K, Ellenberger D, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK.

Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580. [Epub ahead of print]

PMID:
30230952
19.

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.

Ellenberger D, Eichstädt K, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK, Rommer PS.

Mult Scler Relat Disord. 2018 Oct;25:173-174. doi: 10.1016/j.msard.2018.07.040. Epub 2018 Jul 24. No abstract available.

PMID:
30096682
20.

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, Zettl UK.

CNS Neurosci Ther. 2019 Feb;25(2):245-254. doi: 10.1111/cns.13034. Epub 2018 Jul 25.

21.

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.

Koczan D, Fitzner B, Zettl UK, Hecker M.

Sci Data. 2018 Jul 24;5:180145. doi: 10.1038/sdata.2018.145.

22.

Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.

Winkelmann A, Rommer PS, Hecker M, Zettl UK.

CNS Neurosci Ther. 2019 Jan;25(1):78-85. doi: 10.1111/cns.12985. Epub 2018 Jun 1.

23.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.

Rommer PS, Zettl UK.

Lancet Neurol. 2018 Jun;17(6):497-498. doi: 10.1016/S1474-4422(18)30161-3. No abstract available.

PMID:
29778357
24.

The sphingosine analog fingolimod (FTY720) enhances tone and contractility of rat gastric fundus smooth muscle.

Kraft M, Zettl UK, Noack T, Patejdl R.

Neurogastroenterol Motil. 2018 Oct;30(10):e13372. doi: 10.1111/nmo.13372. Epub 2018 May 8.

PMID:
29740911
25.

Coping behavior in multiple sclerosis-complementary and alternative medicine: A cross-sectional study.

Rommer PS, König N, Sühnel A, Zettl UK.

CNS Neurosci Ther. 2018 Sep;24(9):784-789. doi: 10.1111/cns.12857. Epub 2018 Apr 10.

26.

Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.

Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbäumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE).

Ann Neurol. 2018 Apr;83(4):863-869. doi: 10.1002/ana.25216.

PMID:
29572931
27.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
28.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
29.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

30.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
31.

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Löbermann M, Handorn B, Winkelmann A, Reisinger EC, Hartung HP, Zettl UK.

Nervenarzt. 2018 Oct;89(10):1172-1178. doi: 10.1007/s00115-018-0492-6. Review. German.

PMID:
29404651
32.

Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge.

Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS.

Expert Rev Clin Immunol. 2018 Feb;14(2):137-153. doi: 10.1080/1744666X.2018.1426462. Epub 2018 Jan 23.

PMID:
29318902
33.

Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.

Angerer IC, Hecker M, Koczan D, Roch L, Friess J, Rüge A, Fitzner B, Boxberger N, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Meister S, Zettl UK.

CNS Neurosci Ther. 2018 Mar;24(3):193-201. doi: 10.1111/cns.12793. Epub 2018 Jan 3.

34.

Headache in the first manifestation of Multiple Sclerosis - Prospective, multicenter study.

Gebhardt M, Kropp P, Jürgens TP, Hoffmann F, Zettl UK.

Brain Behav. 2017 Nov 16;7(12):e00852. doi: 10.1002/brb3.852. eCollection 2017 Dec.

35.

Information processing deficits as a driving force for memory impairment in MS: A cross--sectional study of memory functions and MRI in early and late stage MS.

Köhler W, Fischer M, Bublak P, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Stadler E, Zettl UK, Penner IK; HIPPOCOMS Study Group.

Mult Scler Relat Disord. 2017 Nov;18:119-127. doi: 10.1016/j.msard.2017.09.026. Epub 2017 Sep 25.

PMID:
29141793
36.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2018 Oct;24(11):1507-1510. doi: 10.1177/1352458517739137. Epub 2017 Nov 9.

37.

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.

Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK.

Int J Mol Sci. 2017 Aug 11;18(8). pii: E1749. doi: 10.3390/ijms18081749.

38.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

39.

Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions.

Patejdl R, Zettl UK.

Autoimmun Rev. 2017 Sep;16(9):925-936. doi: 10.1016/j.autrev.2017.07.004. Epub 2017 Jul 8. Review.

PMID:
28698092
40.

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.

Friess J, Hecker M, Roch L, Koczan D, Fitzner B, Angerer IC, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Zettl UK.

Sci Rep. 2017 Feb 3;7:42087. doi: 10.1038/srep42087.

41.

The Development of Sayk's Cell Sedimentation Chamber: A Historical View on Clinical Cerebrospinal Fluid Diagnostics.

Dahlmann N, Zettl UK, Kumbier E.

Eur Neurol. 2017;77(3-4):162-167. doi: 10.1159/000456003. Epub 2017 Jan 25.

42.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

43.

[Diagnostic Workup and Treatment of Antibody-Related Encephalomyelitis].

Patejdl R, Winkelmann A, Ehler J, Zettl H, Meister S, Zettl UK.

Fortschr Neurol Psychiatr. 2016 Oct;84(S 02):S88-S91. Epub 2016 Nov 2. Review. German.

PMID:
27806422
44.

[Autoimmune-Mediated Encephalomyelitis: a Heterogeneous Entity in Between Neurology and Psychiatry].

Zettl UK, Dudesek A, Rimmele F, Zettl H, Patejdl R.

Fortschr Neurol Psychiatr. 2016 Oct;84(S 02):S84-S87. Epub 2016 Nov 2. Review. German.

PMID:
27806421
45.

Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.

Zettl UK, Schreiber H, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; BETAPATH Study Group.

Acta Neurol Scand. 2017 Aug;136(2):116-121. doi: 10.1111/ane.12705. Epub 2016 Oct 30.

PMID:
27796033
46.

Hans Queckenstedt (1876-1918).

Kumbier E, Zettl UK.

J Neurol. 2017 May;264(5):1032-1034. doi: 10.1007/s00415-016-8315-9. Epub 2016 Oct 19. No abstract available.

PMID:
27761642
47.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

48.

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms.

Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L.

Sci Rep. 2016 Oct 3;6:34512. doi: 10.1038/srep34512.

49.

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; Study Group.

BMC Neurol. 2016 Sep 21;16(1):181.

50.

Neuromyelitis optica spectrum disorder coinciding with hematological immune disease: A case report.

Patejdl R, Wittstock M, Zettl UK, Jost K, Grossmann A, Prudlo J.

Mult Scler Relat Disord. 2016 Sep;9:101-3. doi: 10.1016/j.msard.2016.07.006. Epub 2016 Jul 8.

PMID:
27645353

Supplemental Content

Loading ...
Support Center